Zentalis (ZNTL) Q2 Loss Narrows 70%

Zentalis Pharmaceuticals (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on developing cancer therapies, released its second quarter earnings on August 6, 2025. The headline news was a much narrower net loss per share than forecast: it posted a GAAP EPS of $0.37 for Q2 2025, better than analyst projections of a $(0.59) loss. As in past periods, it reported no revenue. Zentalis extended its cash runway well into 2027. Overall, the period reflects tighter financial discipline and progress on restructuring, with investors waiting for critical clinical trial data.

Source: Analyst estimates for the quarter provided by FactSet.

Zentalis Pharmaceuticals is a biotechnology company developing targeted therapies for cancer. Its main product candidate is azenosertib, a WEE1 inhibitor designed to treat certain hard-to-treat cancers.

Continue reading

Source Fool.com